Parameter
| Biomarker | TP53 | Full name | Tumor protein p53 | Molecular Type | Nucleic acid（DNA） |
|---|---|---|---|---|---|
| Molecular Formula | / | Molecular Weight | / | Core Functional Dimensions | Prognosis |
| Disease | Endometrial Cancer | Disease Subtypes | / | ||
| Organ | Endometrium | Test Sample / Technology Platform | Organization (IHC, NGS) | ||
| Pathobiological Mechanisms | Tumor suppressor genes, when mutated, lead to the loss of function of the p53 protein, which is unable to regulate the cell cycle and apoptosis, promoting malignant transformation. | ||||
| Clinical Availability Status | Clinical recommendation (classification / prognosis): The mutation rate of serous carcinoma exceeds 80%, which is a core biomarker for the high-risk subtype. | ||||
| Notes and Dynamics | The mutant patients are mostly of the high-risk type, with a high risk of recurrence after surgery, and thus require intensified adjuvant therapy. | ||||